Article Text

other Versions

Download PDFPDF
Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?
  1. Ashwin Radhakrishnan1,2,
  2. Luke C Pickup1,2,
  3. Anna M Price1,3,
  4. Jonathan P Law1,3,
  5. Nicola C Edwards1,4,
  6. Richard P Steeds1,2,
  7. Charles J Ferro1,3,
  8. Jonathan N Townend1,2
  1. 1Birmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
  2. 2Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK
  3. 3Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham, UK
  4. 4Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
  1. Correspondence to Professor Jonathan N Townend; john.townend{at}uhb.nhs.uk

Abstract

The syndrome of uraemic cardiomyopathy, characterised by left ventricular hypertrophy, diffuse fibrosis and systolic and diastolic dysfunction, is common in chronic kidney disease and is associated with an increased risk of cardiovascular morbidity and mortality. The pathophysiological mechanisms leading to uraemic cardiomyopathy are not fully understood. We suggest that coronary microvascular dysfunction may be a key mediator in the development of uraemic cardiomyopathy, a phenomenon that is prevalent in other myocardial diseases that share phenotypical similarities with uraemic cardiomyopathy such as hypertrophic cardiomyopathy and heart failure with preserved ejection fraction. Here, we review the current understanding of uraemic cardiomyopathy, highlight different methods of assessing coronary microvascular function and evaluate the current evidence for coronary microvascular dysfunction in chronic kidney disease.

  • myocardial disease
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors contributed to the writing of this manuscript: conception of the review (AR, CJF and JNT), drafting of the manuscript (AR, RPS, CJF and JNT) and critical revision of the manuscript (all authors).

  • Funding AR is funded by a Birmingham Health Partners Starter Fellowship. LCP, AMP and JPL are holders of British Heart Foundation Clinical Research Training Fellowships.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Author note References with a w can be found in the supplementary material which is loaded online with this article.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.